ANGLE says Queen Mary University patent could pave the way for a new use for its technology

The company's Parsortix device was used to harvest bone marrow cells called megakaryocytes


ANGLE PLC (LON:AGL OTCQX:ANPCY) said Queen Mary University of London has been awarded a European patent over a new and potentially ground-breaking method of cancer prognosis that uses the company’s liquid biopsy.

The AIM-listed med-tech firm has an option to take ownership of the procedure that is in place until June 2021 that allows it to expand the array of tests offered by its Parsortix device.

Queen Mary’s approach was to use the ANGLE technology to process blood so megakaryocyte cells could be counted.

There was a strong correlation between the number of these large bone marrow cells and patient survival, researchers found when assessing prostate cancer sufferers.

“We welcome the acceptance of this European patent and are excited by the potential for this entirely new way of assessing cancer through a simple blood test that has been enabled by ANGLE’s Parsortix system,” said chief executive Andrew Newland.

“We will now be investigating the possibility of adding megakaryocyte tests to our existing CTC [circulating tumour] tests as part of our sample-to-answer imaging solution under development.”

Parsortix is currently the only automated system that has demonstrated the capability of harvesting megakaryocytes. 

The company said patents in other countries are being sought for the new method of assessing for cancer.

Quick facts: ANGLE PLC

Price: 40.581 GBX

Market: AIM
Market Cap: £87.41 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...


ANGLE completes FDA submission for Parsortix system for metastatic breast cancer

ANGLE PLC's (LON:AGL, OTCQX:ANPCY) Andrew Newland talks to Proactive's Katie Pilbeam after announcing the completion of their submission to the FDA for its Parsortix PC1 liquid biopsy for use in women with metastatic breast cancer (MBC). Newland calls the announcement 'a massive day' after...

on 28/9/20

2 min read